European Journal of Clinical Pharmacology
2008-01-01
Tofisopam inhibits the pharmacokinetics of CYP3A4 substrate midazolam.
Mária Tóth, Sándor Drabant, Bálint Varga, Gyula Végso, Anna Cseh, Imre Szentpéteri, Imre Klebovich
Index: Eur. J. Clin. Pharmacol. 64(1) , 93-4, (2008)
Full Text: HTML
Abstract
Related Articles:
The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis.
2010-11-01
[J. Neural Transm. Gen. Sect. 117(11) , 1319-25, (2010)]
[Pineal hormone melatonin in low doses potentiates psychotropic and chronotropic activity of tofisopam in rats].
2013-01-01
[Eksp. Klin. Farmakol. 76(4) , 15-7, (2013)]
Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome.
2008-01-15
[Aliment. Pharmacol. Ther. 27(2) , 197-206, (2008)]
Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling.
2007-05-15
[Toxicol. Appl. Pharmacol. 221(1) , 111-8, (2007)]
Method validation and determination of enantiomers and conformers in tofisopam drug substances and drug products by chiral high-performance liquid chromatography and kinetic and thermodynamic study of the interconversion of the conformers.
2006-09-29
[J. Chromatogr. A. 1129(1) , 47-53, (2006)]